ClearPoint Neuro, Inc.
NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact Information
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
Market Cap
$350.73M
P/E (TTM)
-13.1
23.8
Dividend Yield
--
52W High
$30.10
52W Low
$8.27
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$10.41M+0.00%
4-Quarter Trend
EPS
-$0.27+0.00%
4-Quarter Trend
FCF
-$12.13M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Rises 18% Total revenue reached $37.0M USD, marking an 18% increase driven by product sales growth across segments.
Product Sales Surge 28% Product revenue grew 28% to $23.9M USD; neurosurgery disposable sales increased 44% year-over-year.
IRRAS Acquisition Closed Completed IRRAS acquisition in Q4 2025, expanding portfolio into neurocritical care with IRRAflow system integration.
Gross Margin Remains Stable Gross profit reached $22.7M USD; gross margin held steady at 61% despite increased operating costs.
Risk Factors
Net Loss Widens Significantly Net loss increased 35% to $(25.5M) USD in 2025; sustained profitability remains uncertain given ongoing investments.
High Customer Revenue Concentration Significant customer concentration risk exists; top five hospital customers accounted for 21% of 2025 disposable revenues.
Operating Expenses Increase General and administrative expenses rose 38% to $16.5M USD, driven by IRRAS acquisition integration costs.
Market Adoption Uncertainty Future growth hinges on achieving broad market adoption for ClearPoint and IRRAflow systems against established competitors.
Outlook
Anticipated Future Funding Needs Expect need for additional capital following IRRAS acquisition to fund commercialization and integration efforts through 2026.
Expand Installed Base Future objectives depend on expanding installed base and procedure volumes for both ClearPoint and IRRAflow platforms.
Biologics Partner Pipeline Over 60 partners evaluate products for gene/cell therapy delivery; success depends on partner clinical trial outcomes.
Cybersecurity Integration Planned Expect to fully integrate IRRAS cybersecurity governance structure and risk management framework throughout 2026.
Peer Comparison
Revenue (TTM)
$912.10M
$854.40M
$824.50M
Gross Margin (Latest Quarter)
83.5%
79.0%
78.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AXGN | $2.00B | -115.1 | -13.4% | 8.7% |
| TYRA | $1.91B | -17.7 | -41.2% | 2.1% |
| OLMA | $1.47B | -9.5 | -42.9% | 0.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.1%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 11, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data